Soon-to-be AstraZeneca's COPD combi-drug gets CHMP nod
This article was originally published in Scrip
Executive Summary
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the regulatory approval of Duaklir Genuair (aclidinium bromide/formoterol fumarate) as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).